Skip to main content

Table 3 Prior medication use at enrollment in psoriasis patients with self-reported PsA enrolled in PSOLAR; Overall population

From: Serious infections in patients with self-reported psoriatic arthritis from the Psoriasis Longitudinal Assessment and Registry (PSOLAR) treated with biologics

 

Ustekinumab (N = 628)

TNF inhibitorsa (N = 1413)

Infliximab (N = 258)

Etanercept (N = 481)

Adalimumab (N = 674)

Non-biologic /MTXb (N = 98)

Non-biologic /non-MTXc (N = 208)

Alld (N = 2401)

Systemic steroidse

0 (0.0)

0 (0.0)

0 (0.0)

0 (0.0)

0 (0.0)

0 (0.0)

48 (23.1)

48 (2.0)

Immunomodulators

259 (41.2)

568 (40.2)

155 (60.1)

171 (35.6)

242 (35.9)

81 (82.7)

11 (5.3)

947 (39.4)

 Methotrexate

259 (41.2)

568 (40.2)

155 (60.1)

171 (35.6)

242 (35.9)

81 (82.7)

0 (0.0)

936 (39.0)

 Cyclosporine

0 (0.0)

0 (0.0)

0 (0.0)

0 (0.0)

0 (0.0)

0 (0.0)

6 (2.9)

6 (0.2)

 Oral tacrolimus

0 (0.0)

0 (0.0)

0 (0.0)

0 (0.0)

0 (0.0)

0 (0.0)

0 (0.0)

0 (0.0)

 Mycophenolate mofetil

0 (0.0)

0 (0.0)

0 (0.0)

0 (0.0)

0 (0.0)

0 (0.0)

1 (0.5)

1 (< 0.1)

 Other immunomodulatorse

0 (0.0)

0 (0.0)

0 (0.0)

0 (0.0)

0 (0.0)

0 (0.0)

5 (2.4)

5 (0.2)

Topical therapy

609 (97.0)

1381 (97.7)

249 (96.5)

472 (98.1)

660 (97.9)

96 (98.0)

194 (93.3)

2332 (97.1)

Topical steroids

602 (95.9)

1352 (95.7)

244 (94.6)

462 (96.0)

646 (95.8)

94 (95.9)

187 (89.9)

2285 (95.2)

Phototherapy

376 (59.9)

670 (47.4)

142 (55.0)

214 (44.5)

314 (46.6)

37 (37.8)

90 (43.3)

1200 (50.0)

Psoralens + UVA

111 (17.7)

210 (14.9)

56 (21.7)

56 (11.6)

98 (14.5)

13 (13.3)

14 (6.7)

358 (14.9)

Biologics

572 (91.1)

1246 (88.2)

244 (94.6)

409 (85.0)

593 (88.0)

0 (0.0)

0 (0.0)

1869 (77.8)

 Number of biologics used

628

1413

258

481

674

98

208

2401

  0

56 (8.9)

167 (11.8)

14 (5.4)

72 (15.0)

81 (12.0)

98 (100.0)

208 (100.0)

532 (22.2)

  1

207 (33.0)

769 (54.4)

90 (34.9)

318 (66.1)

361 (53.6)

0 (0.0)

0 (0.0)

997 (41.5)

  2

215 (34.2)

342 (24.2)

94 (36.4)

69 (14.3)

179 (26.6)

0 (0.0)

0 (0.0)

569 (23.7)

  3

110 (17.5)

112 (7.9)

48 (18.6)

18 (3.7)

46 (6.8)

0 (0.0)

0 (0.0)

234 (9.7)

  4+

40 (6.4)

23 (1.6)

12 (4.7)

4 (0.8)

7 (1.0)

0 (0.0)

0 (0.0)

69 (2.9)

  1. Data are n (%) unless otherwise indicated
  2. The biologic user cohort includes patients who are on the cohort defining biologic at entry or start the biologic after entry; previous use or current exposure is allowed for MTX, but not for other systemic immunomodulators
  3. MTX methotrexate; PsA psoriatic arthritis; PSOLAR Psoriasis Longitudinal Assessment and Registry; UVA ultraviolet A
  4. a Tumor necrosis factor (TNF) inhibitors includes infliximab, etanercept, and adalimumab
  5. bThe non-biologic/MTX cohort includes patients who are receiving MTX at entry or start methotrexate during the registry and haven’t been exposed to other systemic immunomodulators previously or concurrently
  6. cNon-biologic, non-MTX therapies may include, but are not limited to, cyclosporine, tacrolimus, mycophenolate mofetil, azathioprine, oral corticosteroids, systemic retinoids, psoralen plus ultraviolet (UV), or UVB phototherapy. The non-biologic/non-MTX cohort includes patients who are receiving other systemic immunomodulators (including cyclosporine, tacrolimus, mycophenolate mofetil, other immunomodulators, and oral corticosteroids) at entry or start other immunomodulators after registry and who haven’t been exposed to MTX previously or concurrently; patients who receive only topical and/or phototherapy at/after registry entry are also in this cohort
  7. dIncludes “Other biologics” group (n = 54); data not shown
  8. eProhibited per exclusion criteria
Back to article page

BMC Rheumatology

ISSN: 2520-1026

Contact us